FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:206-207 January 20, 1994 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Adjuvant chemotherapy given after elimination of all macroscopic disease by surgery is now standard therapy for patients with selected solid tumors, such as node-positive colon cancer and breast cancer. Durable local control is usually achieved with primary treatment (surgery with or without radiation therapy) and may be augmented by systemic adjuvant therapy. However, the main target of the chemotherapy is imperceptible metastatic disease that is unaffected by the potentially curative local and regional treatment. Numerous randomized trials have confirmed the benefits of this approach as measured by disease-free and overall survival, and it has become an important component of oncologic . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Strauss, G. M. (1999). Role of Chemotherapy in Stages I to III Non-small Cell Lung Cancer*. Chest 116: 509S-516S [Abstract] [Full Text]